Pharmazz
Willowbrook, US · Founded 2017 · Delaware corporation
Pharmazz is a biopharmaceutical company developing and commercializing therapeutics for critical care and acute medicine, focused on Endothelin-B receptor agonists and resuscitative agents for conditions such as hypovolemic shock, ischemic stroke, and septic shock. Its lead products include Centhaquine (Lyfaquin) for hypovolemic shock and Tyvalzi for cerebral stroke, with operations in the U.S. and India.
BiotechHealthtech
Founders & leadership
AG
Anil GulatiFounder & CEO
DC
David CostelloExecutive Officer
SG
Sunil GulatiExecutive Officer
DS
Daniel StauderExecutive Officer
AS
Ajit SrimalDirector
GT
Gaylord ToftExecutive Vice President
JM
James McDonnellDirector
JK
Jane KiernanDirector
AR
Atul RautDirector
JM
James McConnellDirector
DM
Dharminder MarwahDirector
Competitors · 3
by search overlapDiabetes Prevention Program4 shared keywords
Cleveland Clinic, 20223 shared keywordsCleveland Clinic is a patient-centered academic medical center providing clinical care, research, and medical education. The organization offers services ranging from primary care and virtual visits to specialized treatment, clinical trials, and advanced medical research.
NCT051011873 shared keywords
Companies competing with Pharmazz for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$250KraisedJul 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$250KraisedJul 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Sunil GulatiExecutive Officer
- David CostelloExecutive Officer
- Dharminder MarwahExecutive Officer, Director
- James McDonnellDirector
- Jane KiernanDirector
- Anil GulatiExecutive Officer, Director
- Atul RautDirector
- Offering amount
- $3.5M
- Amount sold
- $250K
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedJun 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$10MraisedJun 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David CostelloExecutive Officer
- Sunil GulatiExecutive Officer
- Dharminder MarwahExecutive Officer, Director
- Anil GulatiExecutive Officer, Director
- Jane KiernanDirector
- James McDonnellDirector
- Offering amount
- $25M
- Amount sold
- $10M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedAug 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$7.5MraisedAug 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David CostelloExecutive Officer
- James McConnellDirector
- Sunil GulatiExecutive Officer
- Daniel StauderExecutive Officer
- Dharminder MarwahDirector
- Anil GulatiExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $7.5M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$150KraisedFeb 2024 · 2 investors · PharmaceuticalsRule 506(b)
▶$150KraisedFeb 2024 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Sunil GulatiExecutive Officer
- Anil GulatiExecutive Officer, Director
- Dharminder MarwahDirector
- James McDonnellDirector
- David CostelloExecutive Officer
- Daniel StauderExecutive Officer
- Offering amount
- $6M
- Amount sold
- $150K
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$450KraisedNov 2023 · 3 investors · PharmaceuticalsRule 506(b)
▶$450KraisedNov 2023 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dharminder MarwahDirector
- David CostelloExecutive Officer
- Anil GulatiExecutive Officer, Director
- Daniel StauderExecutive Officer
- James McDonnellDirector
- Sunil GulatiExecutive Officer
- Offering amount
- $15M
- Amount sold
- $450K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedMay 2023 · 28 investors · PharmaceuticalsRule 506(b)
▶$5.5MraisedMay 2023 · 28 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David CostelloExecutive Officer
- Daniel P. StauderExecutive Officer
- Sunil GulatiExecutive Officer
- Anil GulatiExecutive Officer, Director
- Dharminder MarwahDirector
- James McDonnellDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedMay 2023 · 16 investors · PharmaceuticalsRule 506(b)
▶$2.3MraisedMay 2023 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Daniel StauderExecutive Officer
- James McDonnellDirector
- Sunil GulatiExecutive Officer
- Anil GulatiExecutive Officer, Director
- Dharminder MarwahDirector
- David CostelloExecutive Officer
- Offering amount
- $6.5M
- Amount sold
- $2.3M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedMar 2020 · 1 investors · BiotechnologyRule 506(b)
▶$1.4MraisedMar 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anil GulatiExecutive Officer, Director
- Gaylord ToftExecutive Officer
- Sunil GulatiExecutive Officer
- Ajit SrimalDirector
- Offering amount
- $5M
- Amount sold
- $1.4M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $277.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
- Pharmazz, Inc. Appoints Ajay Bansal as Chief Financial Officerglobenewswire.com · 2026